Pharma ETFs Could Flatline on Obamacare Bust | Page 2 of 2 | ETF Trends

The enrollment into the Affordable Care Act has been hindered by website technical problems, public backlash and political tension. [Help From the Hill Could Add to Pharma ETFs’ Gains]

IMS projects oncology drugs will experience the most spending in developed countries, with sales up to $84 billion in 2017, followed by $39 billion in diabetes drugs. Pain medicines, though, lead in emerging markets with $25 billion in spending.

Pharmaceutical ETFs include:

  • SPDR S&P Pharmaceuticals ETF (NYSEArca: XPH): up 55.1% year-to-date
  • PowerShares Dynamic Pharmaceuticals Portfolio (NYSEArca: PJP): up 49.3% year-to-date
  • iShares U.S. Pharmaceuticals ETF (NYSEArca: IHE): up 37.2% year-to-date
  • Market Vectors Pharmaceutical ETF (NYSEArca: PPH): up 32.0% year-to-date
  • RBS Global Big Pharma ETN (NYSEArca: DRGS): up 35.1% year-to-date

For more information on the pharma sector, visit our pharmaceuticals category.

Max Chen contributed to this article.